Skip to content

Lidocaine For Neuroprotection During Cardiac Surgery

Lidocaine For Neuroprotection During Cardiac Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00938964
Enrollment
550
Registered
2009-07-14
Start date
2009-07-31
Completion date
2017-05-23
Last updated
2019-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Decline

Keywords

Cognition

Brief summary

The purpose of this study is to see if a drug called lidocaine prevents cognitive injury (a decline in mental abilities) after heart surgery. Lidocaine is currently FDA approved and is commonly used for treating some heart rhythm disorders and for regional anesthesia (blocking nerves). The investigators are enrolling subjects in this research project to see if lidocaine will reduce the high incidence of cognitive injury seen after heart surgery. As part of this study, the investigators will also evaluate the relationship between cognitive injury and genetic makeup and the chemical changes in the subjects blood during and after surgery.

Interventions

DRUGLidocaine

Lidocaine versus placebo infusion for 48 hours

DRUGPlacebo

Lidocaine versus placebo infusion for 48 hours

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
CAS Medical Systems, Inc.
CollaboratorINDUSTRY
Duke University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. CABG, CABG + Valve, or Valve surgery 2. Use of cardiopulmonary bypass

Exclusion criteria

1. Less than 50 years of age 2. History of diabetes 3. History of symptomatic cerebrovascular disease (e.g. prior stroke) with residual deficit 4. Alcoholism (\> 2 drinks/day) 5. History of psychiatric illness (any clinical diagnoses requiring therapy) 6. History of drug abuse (any illicit drug use in the past 3 months) 7. Hepatic insufficiency (liver function tests \> 1.5 times the upper limit of normal) 8. Severe pulmonary insufficiency (requiring home oxygen therapy) 9. Renal failure (baseline serum creatinine \> 2.0 mg/dl) 10. Pregnant women 11. Unable to read and thus unable to complete the cognitive testing 12. Score \< 24 on a baseline Mini Mental State examination (MMSE) or greater than or equal to 27 on the baseline Center for Epidemiological Studies Depression (CES-D) Scale -

Design outcomes

Primary

MeasureTime frameDescription
Change in Cognitive Function From Baseline Characterized as Continuous Cognitive ChangePreoperative to 6 weeks after surgeryTo characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 6-week cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement.
Count of Participants With a Decline of Greater Than or Equal to One Standard Deviation in One or More of Five Cognitive Domain Scores Reported as a Dichotomous Post-operative Cognitive Deficit (POCD) OutcomePreoperative to 6 weeks after surgeryTo characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. Each domain score is normally distributed with a mean of zero. A change score was calculated for each domain by subtracting the baseline from the 6-week score. A dichotomous outcome variable of post-operative cognitive deficit was defined as a decline of ≥1 standard deviation in 1 or more of the 5 domains.

Secondary

MeasureTime frameDescription
Transcerebral Activation Gradients of MonocytesBaseline to 6 hours post cross-clamp removalPaired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups
Transcerebral Activation Gradient of Platelet-neutrophil ConjugatesBaseline to 6 hours post cross-clamp removalPaired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups
Change in Cognitive Function From Baseline1 year after surgeryTo characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 1 year cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement
Change in Duke Activity Status Index (DASI)baseline, 6-weeksThe DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function.
Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)baseline, 6-weeksThe National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient).
Change in Center for Epidemiological Studies Depression Scale (CES-D)baseline, 6-weeksCenter for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression.
Change in Spielberger State Anxiety Inventory (STAI)baseline, 6-weeksSpielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety.
Transcerebral Activation Gradients of PlateletsBaseline to 6 hours post cross-clamp removalPaired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups
Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)baseline, 6-weeksDuke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities.
Change in the Cognitive Difficulties Scalebaseline, 6-weeksCognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty.
Change in Perceived Social Supportbaseline, 6-weeksPerceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support.
Change in Social Activitybaseline, 6-weeksSocial Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity.
Change in Study 36-Item Short Form Health Survey (SF-36)baseline, 6-weeksThe Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state.
Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)baseline, 6-weeksThe Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function.
Change in Symptom Limitationsbaseline, 6-weeksSymptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations.
Transcerebral Activation Gradients of NeutrophilsBaseline to 6 hours post cross-clamp removalPaired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removal and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups

Countries

United States

Participant flow

Recruitment details

550 participants consented; 478 participants were randomized.

Participants by arm

ArmCount
Lidocaine
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
211
Placebo
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
209
Total420

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyDeath33
Overall StudyFound to Meet Exclusion Criteria34
Overall StudyLost to Follow-up23
Overall StudyWithdrawal by Subject2218

Baseline characteristics

CharacteristicLidocainePlaceboTotal
Age, Continuous66.9 years
STANDARD_DEVIATION 9.1
66.5 years
STANDARD_DEVIATION 9.5
66.7 years
STANDARD_DEVIATION 9.3
Region of Enrollment
United States
211 Participants209 Participants420 Participants
Sex: Female, Male
Female
60 Participants49 Participants109 Participants
Sex: Female, Male
Male
151 Participants160 Participants311 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
6 / 2417 / 237
other
Total, other adverse events
34 / 24134 / 237
serious
Total, serious adverse events
105 / 241103 / 237

Outcome results

Primary

Change in Cognitive Function From Baseline Characterized as Continuous Cognitive Change

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 6-week cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement.

Time frame: Preoperative to 6 weeks after surgery

ArmMeasureValue (MEAN)Dispersion
LidocaineChange in Cognitive Function From Baseline Characterized as Continuous Cognitive Change0.07 units on a scaleStandard Deviation 0.32
PlaceboChange in Cognitive Function From Baseline Characterized as Continuous Cognitive Change0.07 units on a scaleStandard Deviation 0.37
Primary

Count of Participants With a Decline of Greater Than or Equal to One Standard Deviation in One or More of Five Cognitive Domain Scores Reported as a Dichotomous Post-operative Cognitive Deficit (POCD) Outcome

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. Each domain score is normally distributed with a mean of zero. A change score was calculated for each domain by subtracting the baseline from the 6-week score. A dichotomous outcome variable of post-operative cognitive deficit was defined as a decline of ≥1 standard deviation in 1 or more of the 5 domains.

Time frame: Preoperative to 6 weeks after surgery

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
LidocaineCount of Participants With a Decline of Greater Than or Equal to One Standard Deviation in One or More of Five Cognitive Domain Scores Reported as a Dichotomous Post-operative Cognitive Deficit (POCD) Outcome87 Participants
PlaceboCount of Participants With a Decline of Greater Than or Equal to One Standard Deviation in One or More of Five Cognitive Domain Scores Reported as a Dichotomous Post-operative Cognitive Deficit (POCD) Outcome83 Participants
Secondary

Change in Center for Epidemiological Studies Depression Scale (CES-D)

Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression.

Time frame: baseline, 1-year

Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.

ArmMeasureValue (MEAN)Dispersion
LidocaineChange in Center for Epidemiological Studies Depression Scale (CES-D)-1.27 units on a scaleStandard Deviation 7.7
PlaceboChange in Center for Epidemiological Studies Depression Scale (CES-D)-0.89 units on a scaleStandard Deviation 7.9
Secondary

Change in Center for Epidemiological Studies Depression Scale (CES-D)

Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression.

Time frame: baseline, 6-weeks

ArmMeasureValue (MEAN)Dispersion
LidocaineChange in Center for Epidemiological Studies Depression Scale (CES-D)0.57 units on a scaleStandard Deviation 7.5
PlaceboChange in Center for Epidemiological Studies Depression Scale (CES-D)0.16 units on a scaleStandard Deviation 8.3
Secondary

Change in Cognitive Function From Baseline

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 1 year cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement

Time frame: 1 year after surgery

Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.

ArmMeasureValue (MEAN)Dispersion
LidocaineChange in Cognitive Function From Baseline0.09 units on a scaleStandard Deviation 0.34
PlaceboChange in Cognitive Function From Baseline0.07 units on a scaleStandard Deviation 0.34
Secondary

Change in Duke Activity Status Index (DASI)

The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function.

Time frame: baseline, 1-year

Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.

ArmMeasureValue (MEAN)Dispersion
LidocaineChange in Duke Activity Status Index (DASI)6.3 units on a scaleStandard Deviation 18.3
PlaceboChange in Duke Activity Status Index (DASI)6.96 units on a scaleStandard Deviation 16.9
Secondary

Change in Duke Activity Status Index (DASI)

The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function.

Time frame: baseline, 6-weeks

ArmMeasureValue (MEAN)Dispersion
LidocaineChange in Duke Activity Status Index (DASI)-10.98 units on a scaleStandard Deviation 15.4
PlaceboChange in Duke Activity Status Index (DASI)-11.67 units on a scaleStandard Deviation 16.8
Secondary

Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)

The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient).

Time frame: baseline, 6-weeks

ArmMeasureValue (MEAN)Dispersion
LidocaineChange in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)0.05 units on a scaleStandard Deviation 0.5
PlaceboChange in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)0.04 units on a scaleStandard Deviation 0.5
Secondary

Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)

The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient).

Time frame: baseline, 1-year

Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.

ArmMeasureValue (MEAN)Dispersion
LidocaineChange in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)0.05 units on a scaleStandard Deviation 0.7
PlaceboChange in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)0.07 units on a scaleStandard Deviation 0.6
Secondary

Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)

The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function.

Time frame: baseline, 1-year

Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.

ArmMeasureValue (MEAN)Dispersion
LidocaineChange in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)0.02 units on a scaleStandard Deviation 1.1
PlaceboChange in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)-0.02 units on a scaleStandard Deviation 1.2
Secondary

Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)

The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function.

Time frame: baseline, 6-weeks

ArmMeasureValue (MEAN)Dispersion
LidocaineChange in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)0.04 units on a scaleStandard Deviation 1.1
PlaceboChange in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)-0.01 units on a scaleStandard Deviation 1.3
Secondary

Change in Perceived Social Support

Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support.

Time frame: baseline, 1-year

Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.

ArmMeasureValue (MEAN)Dispersion
LidocaineChange in Perceived Social Support0.71 units on a scaleStandard Deviation 13.4
PlaceboChange in Perceived Social Support-1.16 units on a scaleStandard Deviation 12.9
Secondary

Change in Perceived Social Support

Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support.

Time frame: baseline, 6-weeks

ArmMeasureValue (MEAN)Dispersion
LidocaineChange in Perceived Social Support1.23 units on a scaleStandard Deviation 14
PlaceboChange in Perceived Social Support-0.49 units on a scaleStandard Deviation 13.9
Secondary

Change in Social Activity

Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity.

Time frame: baseline, 1-year

Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.

ArmMeasureValue (MEAN)Dispersion
LidocaineChange in Social Activity-0.20 units on a scaleStandard Deviation 3.2
PlaceboChange in Social Activity0.03 units on a scaleStandard Deviation 3.4
Secondary

Change in Social Activity

Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity.

Time frame: baseline, 6-weeks

ArmMeasureValue (MEAN)Dispersion
LidocaineChange in Social Activity0.95 units on a scaleStandard Deviation 3.4
PlaceboChange in Social Activity1.59 units on a scaleStandard Deviation 3.2
Secondary

Change in Spielberger State Anxiety Inventory (STAI)

Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety.

Time frame: baseline, 6-weeks

ArmMeasureValue (MEAN)Dispersion
LidocaineChange in Spielberger State Anxiety Inventory (STAI)-7.12 units on a scaleStandard Deviation 12.1
PlaceboChange in Spielberger State Anxiety Inventory (STAI)-6.31 units on a scaleStandard Deviation 11.4
Secondary

Change in Spielberger State Anxiety Inventory (STAI)

Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety.

Time frame: baseline, 1-year

Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.

ArmMeasureValue (MEAN)Dispersion
LidocaineChange in Spielberger State Anxiety Inventory (STAI)-6.70 units on a scaleStandard Deviation 12.7
PlaceboChange in Spielberger State Anxiety Inventory (STAI)-6.39 units on a scaleStandard Deviation 10.3
Secondary

Change in Study 36-Item Short Form Health Survey (SF-36)

The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state.

Time frame: baseline, 6-weeks

ArmMeasureGroupValue (MEAN)Dispersion
LidocaineChange in Study 36-Item Short Form Health Survey (SF-36)6-Week Change Work activities2.71 units on a scaleStandard Deviation 4.9
LidocaineChange in Study 36-Item Short Form Health Survey (SF-36)6-Week Change General health perception-0.004 units on a scaleStandard Deviation 1.3
PlaceboChange in Study 36-Item Short Form Health Survey (SF-36)6-Week Change Work activities3 units on a scaleStandard Deviation 4.3
PlaceboChange in Study 36-Item Short Form Health Survey (SF-36)6-Week Change General health perception-0.03 units on a scaleStandard Deviation 1.2
Secondary

Change in Study 36-Item Short Form Health Survey (SF-36)

The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state.

Time frame: baseline, 1-year

Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.

ArmMeasureGroupValue (MEAN)Dispersion
LidocaineChange in Study 36-Item Short Form Health Survey (SF-36)1 year Change Work Activities-1.37 units on a scaleStandard Deviation 4.3
LidocaineChange in Study 36-Item Short Form Health Survey (SF-36)1 year Change General health perception-0.28 units on a scaleStandard Deviation 1.2
PlaceboChange in Study 36-Item Short Form Health Survey (SF-36)1 year Change Work Activities-1.42 units on a scaleStandard Deviation 4.1
PlaceboChange in Study 36-Item Short Form Health Survey (SF-36)1 year Change General health perception-0.43 units on a scaleStandard Deviation 1.1
Secondary

Change in Symptom Limitations

Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations.

Time frame: baseline, 1-year

Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.

ArmMeasureValue (MEAN)Dispersion
LidocaineChange in Symptom Limitations-1.39 units on a scaleStandard Deviation 3.8
PlaceboChange in Symptom Limitations-1.48 units on a scaleStandard Deviation 3.8
Secondary

Change in Symptom Limitations

Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations.

Time frame: baseline, 6-weeks

ArmMeasureValue (MEAN)Dispersion
LidocaineChange in Symptom Limitations-0.67 units on a scaleStandard Deviation 4
PlaceboChange in Symptom Limitations-0.8 units on a scaleStandard Deviation 3.9
Secondary

Change in the Cognitive Difficulties Scale

Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty.

Time frame: baseline, 6-weeks

ArmMeasureValue (MEAN)Dispersion
LidocaineChange in the Cognitive Difficulties Scale-3 units on a scaleStandard Deviation 14.6
PlaceboChange in the Cognitive Difficulties Scale-3.21 units on a scaleStandard Deviation 15.9
Secondary

Change in the Cognitive Difficulties Scale

Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty.

Time frame: baseline, 1-year

Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.

ArmMeasureValue (MEAN)Dispersion
LidocaineChange in the Cognitive Difficulties Scale-0.46 units on a scaleStandard Deviation 16.1
PlaceboChange in the Cognitive Difficulties Scale-1.02 units on a scaleStandard Deviation 17
Secondary

Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)

Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities.

Time frame: baseline, 1-year

Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.

ArmMeasureValue (MEAN)Dispersion
LidocaineChange in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)-0.15 units on a scaleStandard Deviation 2.1
PlaceboChange in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)-0.31 units on a scaleStandard Deviation 2.6
Secondary

Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)

Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities.

Time frame: baseline, 6-weeks

ArmMeasureValue (MEAN)Dispersion
LidocaineChange in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)2.46 units on a scaleStandard Deviation 4.2
PlaceboChange in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)2.1 units on a scaleStandard Deviation 3.9
Secondary

Transcerebral Activation Gradient of Platelet-neutrophil Conjugates

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups

Time frame: Baseline to 6 hours post cross-clamp removal

Population: Planned substudy, that was analyzed after 202 enrolled subjects.

ArmMeasureGroupValue (MEAN)Dispersion
LidocaineTranscerebral Activation Gradient of Platelet-neutrophil ConjugatesBaseline-0.15 Mean linear fluorescence intensity-MLFIStandard Deviation 9.64
LidocaineTranscerebral Activation Gradient of Platelet-neutrophil ConjugatesCross-clamp removal0.02 Mean linear fluorescence intensity-MLFIStandard Deviation 4.33
LidocaineTranscerebral Activation Gradient of Platelet-neutrophil ConjugatesEnd of Bypass-0.73 Mean linear fluorescence intensity-MLFIStandard Deviation 4.99
LidocaineTranscerebral Activation Gradient of Platelet-neutrophil Conjugates6 hours post cross-clamp removal-0.10 Mean linear fluorescence intensity-MLFIStandard Deviation 5.4
PlaceboTranscerebral Activation Gradient of Platelet-neutrophil Conjugates6 hours post cross-clamp removal0.19 Mean linear fluorescence intensity-MLFIStandard Deviation 4.73
PlaceboTranscerebral Activation Gradient of Platelet-neutrophil ConjugatesBaseline-0.43 Mean linear fluorescence intensity-MLFIStandard Deviation 8.4
PlaceboTranscerebral Activation Gradient of Platelet-neutrophil ConjugatesEnd of Bypass-0.40 Mean linear fluorescence intensity-MLFIStandard Deviation 5.12
PlaceboTranscerebral Activation Gradient of Platelet-neutrophil ConjugatesCross-clamp removal-0.73 Mean linear fluorescence intensity-MLFIStandard Deviation 3.97
Secondary

Transcerebral Activation Gradients of Monocytes

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups

Time frame: Baseline to 6 hours post cross-clamp removal

Population: Planned substudy, that was analyzed after 202 enrolled subjects.

ArmMeasureGroupValue (MEAN)Dispersion
LidocaineTranscerebral Activation Gradients of MonocytesBaseline-4.22 Mean linear fluorescence intensity-MLFIStandard Deviation 19.1
LidocaineTranscerebral Activation Gradients of MonocytesCross-clamp removal-2.46 Mean linear fluorescence intensity-MLFIStandard Deviation 16.94
LidocaineTranscerebral Activation Gradients of MonocytesEnd of Bypass-0.34 Mean linear fluorescence intensity-MLFIStandard Deviation 19.57
LidocaineTranscerebral Activation Gradients of Monocytes6 hours post cross-clamp removal1.21 Mean linear fluorescence intensity-MLFIStandard Deviation 15.08
PlaceboTranscerebral Activation Gradients of Monocytes6 hours post cross-clamp removal0.54 Mean linear fluorescence intensity-MLFIStandard Deviation 13.69
PlaceboTranscerebral Activation Gradients of MonocytesBaseline-0.04 Mean linear fluorescence intensity-MLFIStandard Deviation 17.78
PlaceboTranscerebral Activation Gradients of MonocytesEnd of Bypass2.64 Mean linear fluorescence intensity-MLFIStandard Deviation 15.69
PlaceboTranscerebral Activation Gradients of MonocytesCross-clamp removal1.83 Mean linear fluorescence intensity-MLFIStandard Deviation 16.8
Secondary

Transcerebral Activation Gradients of Neutrophils

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removal and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups

Time frame: Baseline to 6 hours post cross-clamp removal

Population: Planned substudy, that was analyzed after 202 enrolled subjects

ArmMeasureGroupValue (MEAN)Dispersion
LidocaineTranscerebral Activation Gradients of NeutrophilsBaseline-2.02 Mean linear fluorescence intensity-MLFIStandard Deviation 8.15
LidocaineTranscerebral Activation Gradients of NeutrophilsCross-clamp removal0.56 Mean linear fluorescence intensity-MLFIStandard Deviation 6.82
LidocaineTranscerebral Activation Gradients of NeutrophilsEnd of Bypass0.58 Mean linear fluorescence intensity-MLFIStandard Deviation 4.54
LidocaineTranscerebral Activation Gradients of Neutrophils6 hours post cross-clamp removal1.04 Mean linear fluorescence intensity-MLFIStandard Deviation 7.08
PlaceboTranscerebral Activation Gradients of Neutrophils6 hours post cross-clamp removal-0.68 Mean linear fluorescence intensity-MLFIStandard Deviation 8.61
PlaceboTranscerebral Activation Gradients of NeutrophilsBaseline-0.08 Mean linear fluorescence intensity-MLFIStandard Deviation 9.17
PlaceboTranscerebral Activation Gradients of NeutrophilsEnd of Bypass1.19 Mean linear fluorescence intensity-MLFIStandard Deviation 6.76
PlaceboTranscerebral Activation Gradients of NeutrophilsCross-clamp removal0.17 Mean linear fluorescence intensity-MLFIStandard Deviation 5.53
Secondary

Transcerebral Activation Gradients of Platelets

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups

Time frame: Baseline to 6 hours post cross-clamp removal

Population: Planned substudy, that was analyzed after 202 enrolled subjects

ArmMeasureGroupValue (MEAN)Dispersion
LidocaineTranscerebral Activation Gradients of PlateletsBaseline-0.03 Mean linear fluorescence intensity-MLFIStandard Deviation 0.79
LidocaineTranscerebral Activation Gradients of PlateletsCross-clamp removal0.03 Mean linear fluorescence intensity-MLFIStandard Deviation 1.21
LidocaineTranscerebral Activation Gradients of PlateletsEnd of Bypass0.33 Mean linear fluorescence intensity-MLFIStandard Deviation 3.25
LidocaineTranscerebral Activation Gradients of Platelets6 hours post cross-clamp removal0.37 Mean linear fluorescence intensity-MLFIStandard Deviation 2.65
PlaceboTranscerebral Activation Gradients of Platelets6 hours post cross-clamp removal0.27 Mean linear fluorescence intensity-MLFIStandard Deviation 1.07
PlaceboTranscerebral Activation Gradients of PlateletsBaseline0.35 Mean linear fluorescence intensity-MLFIStandard Deviation 1.91
PlaceboTranscerebral Activation Gradients of PlateletsEnd of Bypass0.05 Mean linear fluorescence intensity-MLFIStandard Deviation 2.65
PlaceboTranscerebral Activation Gradients of PlateletsCross-clamp removal0.43 Mean linear fluorescence intensity-MLFIStandard Deviation 1.44

Source: ClinicalTrials.gov · Data processed: Mar 12, 2026